1,281 results on '"Singal, Ashwani"'
Search Results
152. Mesenteric Venous Thrombosis
153. MELD Stratified Outcomes Among Recipients With Diabetes or Hypertension: Simultaneous Liver Kidney Versus Liver Alone
154. Cardiovascular mortality among liver transplant recipients with nonalcoholic steatohepatitis in the United States—a retrospective study
155. Low-Dose Hydroxychloroquine Is as Effective as Phlebotomy in Treatment of Patients With Porphyria Cutanea Tarda
156. Nutrition in Alcoholic Liver Disease
157. Autoimmune Markers Do Not Impact Clinical Presentation or Natural History of Steatohepatitis-Related Liver Disease
158. The impact of the COVID‐19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry
159. Association of Previous Gastric Bypass Surgery and Patient Outcomes in Alcohol-Associated Cirrhosis Hospitalizations
160. Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease
161. Lean non-alcoholic fatty liver disease patients from the global NASH registry
162. The number of public health policies reduces the burden and mortality of alcohol-associated liver disease worldwide: a call for action
163. Impact of COVID-19 on the liver transplant activity in the US: variation by the region, etiology, and cirrhosis complications
164. Alcohol associated hepatitis in Latin America: results from the AH-LATIN study
165. Impact of medical eligibility criteria and OPTN policy on simultaneous liver kidney allocation and utilization
166. Identifying Alcohol Use Disorder in Patients With Cirrhosis Reduces 30-Days Readmission Rate
167. Mo1546 INCREASING TRENDS ON ALCOHOL-ASSOCIATED LIVER DISEASE AND METABOLIC-ASSOCIATED STEATOHEPATITIS IN SPECIFIC CANDIDATE GROUPS AMONG LIVER TRANSPLANT LISTINGS
168. Mo1537 NIAAA CLINICAL CRITERIA FOR THE DIAGNOSIS OF ALCOHOLASSOCIATED HEPATITIS ARE PRECISE IN SEVERE BUT NOT IN MODERATE ALCOHOL-ASSOCIATED HEPATITIS
169. Mo1530 WAITLIST AND POST-TRANSPLANT OUTCOMES OF MET-ALD ARE POORER COMPARED TO THOSE WITH ALD PATIENTS
170. Mo1523 RESPONSE CHANGES IN SERUM MAGNESIUM LEVELS IN PATIENTS WITH SEVERE ALCOHOL-ASSOCIATED HEPATITIS CORRESPOND WITH SEVERITY-ASSOCIATED PROGNOSTIC OUTCOMES
171. Mo1506 ONE-MONTH NATURAL HISTORY ASSESSMENT OF TH-CELL AXIS RELATED INFLAMMATORY CYTOKINES, IL-17 AND IL-22 AND THEIR ROLE IN ALCOHOL-ASSOCIATED LIVER DISEASE.
172. Su1537 MACHINE LEARNING ADVANCED FIBROSIS AND AT-RISK MASH (ALADDIN) WITH A WEB-BASED CALCULATOR FOR PROBABILITY PREDICTION
173. Response to comments on 'Changing landscape of alcohol‐associated liver disease in younger individuals, women and ethnic minorities'.
174. Alcoholic Hepatitis: Prognostic Models and Treatment
175. Antibiotic Prophylaxis for Upper Gastrointestinal Bleed in Liver Cirrhosis; Less May Be More
176. Blood phosphatidylethanol testing and liver transplant eligibility selection: A step closer
177. High‐risk liver transplant recipients with grade 3 acute on chronic liver failure should receive the good quality graft
178. Metastatic tumors to the pancreas: Balancing clinical impression with cytology findings
179. Prevalence and factors affecting occurrence of type 2 diabetes mellitus in Saudi patients with chronic liver disease
180. Reply to ‘‘Alcohol and Liver Transplantation’’
181. Corticosteroids and occurrence of and mortality from infections in severe alcoholic hepatitis: a meta-analysis of randomized trials
182. Therapeutic Strategies for the Treatment of Alcoholic Hepatitis
183. Simultaneous Management of Alcohol Use Disorder and Liver Disease: A Systematic Review and Meta-analysis.
184. Therapeutic Pipeline in Alcohol-Associated Liver Disease.
185. Percutaneous transesophageal gastrostomy tube placement: an alternative to percutaneous endoscopic gastrostomy in patients with intra-abdominal metastasis
186. P-30 IMPACT OF PUBLIC HEALTH POLICIES ON ALCOHOL-ASSOCIATED LIVER DISEASE IN LATIN AMERICA: AN ECOLOGICAL MULTI-NATIONAL STUDY
187. Variability in Survival of Very Low Birth Weight Neonates in Hospitals of India
188. Sending an SOS: Healing the Liver with the Bone Marrow
189. Racial and Health Disparities among Cirrhosis-related Hospitalizations in the USA
190. Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction
191. Ethnic Minorities and Low Socioeconomic Status Patients With Chronic Liver Disease Are at Greatest Risk of Being Uninsured
192. Research methodologies to address clinical unmet needs and challenges in alcohol‐associated liver disease
193. Review of: "A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)"
194. A Review of the Diagnosis and Treatment of Alcohol-Associated Liver Disease—Reply
195. 140. Antibiotic Prophylaxis for Upper Gastrointestinal Bleed in Liver Cirrhosis: Less May Be More
196. Role of Intravenous Albumin as an Adjuvant to Antibiotics for Non-SBP Infections in Patients with Cirrhosis
197. Liver Transplantation for Alcoholic Hepatitis: A Survey of Liver Transplant Centers
198. Transplantation for Nonalcoholic Steatohepatitis
199. S1154 Direct-Acting Oral Anticoagulant and Warfarin Use in Patients With Advanced Cirrhosis
200. S1153 Antibiotic Prophylaxis for Upper Gastrointestinal Bleed in Liver Cirrhosis; Less May Be More
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.